Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 14 Issue 1, March 2020

Volume 14 Issue 1

In this issue...

• Dealmaking in oncology diversifies

• Biopharma’s big year for M&As

Cover image: Immunofluorescence confocal imaging of melanoma cancer cells. Nicola Ferrari RF / Alamy Stock Photo.

Dealmaking in oncology diversifies

    Feature

  • News Feature |

    While dealmaking in oncology continued to feature immunotherapies—particularly multi-targeted agents—there was also diversification, with prominent deals for precision medicine and novel platform technologies.

    • Sarah Hardison
  • Profiles

  • Advertisement Feature |

    Medivir is developing tumor-directed nucleotide oral prodrugs to treat cancers with highly unmet medical needs. The company’s lead drug candidate, MIV-818, is a liver cancer targeted prodrug that Medivir is looking to develop alone in the USA and the EU and through partnerships elsewhere.

    • Medivir
  • Advertisement Feature |

    By supporting research, development and licensing behind its portfolio of companies KDDF is translating Korean science into breakthrough oncology treatments.

    • Korea Drug Development Fund
  • Advertisement Feature |

    Immuno-oncology company Affimed is harnessing the power of innate immunity, with the help of its ROCK (Redirected Optimized Cell Killing) platform to change the lives of patients with cancer

    • Affimed

Biopharma’s big year for M&As

    Feature

  • News Feature |

    M&A activity in the biopharma industry continued to boom last year, with more than 200 deals collectively worth over $200 billion.

    • Biopharma Dealmakers
    • DealForma
  • Profiles

  • Advertisement Feature |

    By harvesting stem cells from umbilical cord blood and differentiating them into natural killer cells, Glycostem has developed oNKord, an affordable off-the-shelf cell therapy product indicated for oncology therapies that is ready to ship worldwide within 48hours

    • Glycostem

Search

Quick links